# Epitalon Side Effects: What the Research Literature Reports > Epitalon side effects in published studies: zero serious adverse events reported across the indexed record, including a 162-patient human cohort and 266-patient mortality study. Epitalon safety literature reviewed and cited. ## What Side Effects Has Epitalon Research Documented? In published studies, epitalon-treated subjects reported no serious adverse effects. The C3H/He mouse carcinogenesis study noted explicitly: "no toxic effects observed" [8]. The 162-patient retinitis pigmentosa study reported no adverse effects [16]. The 266-patient 6-8 year mortality study did not report adverse events [9]. In the 2022 mouse oocyte study, epitalon at 0.1 mM produced protective effects without observed cytotoxicity [17]. The 2025 cell culture study by Al-Dulaimi et al. treated normal human fibroblasts and mammary epithelial cells over three weeks and reported normal cellular behavior with no transformation indicators [22]. Absence of reported adverse events in published studies is not equivalent to controlled long-term safety characterization. ## What Do Studies Report About Epitalon Safety? Existing published studies report low toxicity and no serious adverse events across the indexed record. However, long-term controlled human safety data do not exist to the standard of Western regulatory requirements. The 2025 systematic review explicitly flags: "Additional studies on its potential short- and long-term toxicity are essential" and notes that genotoxicity and carcinogenic potential are not fully characterized [21]. ## Epitalon and Cancer Risk: What Telomerase Research Shows Telomerase activation is a double-edged mechanism: while it extends replicative lifespan in normal somatic cells, telomerase overexpression is a feature of approximately 85-90% of human cancers. The existing animal evidence runs counter to the oncological concern: multiple rodent carcinogenesis studies found epitalon did not promote tumor growth, and several showed antitumor effects — reducing colon carcinogenesis [5][6], inhibiting mammary tumor development [7], preventing metastasis in the C3H/He model [8], and reducing HER-2/neu oncogene expression 3.7-fold in transgenic mice [7]. However, the 2025 Biogerontology study found epitalon elevated hTERT expression in cancer cell lines and triggered ALT (alternative lengthening of telomeres) activity — a 10-fold ALT increase in 21NT cells [22]. This cell-type-specific mechanism differentiation has implications for oncology safety assessment. No suppression of endogenous pineal function has been reported in published studies [21]. The bidirectional melatonin regulation observed is consistent with adaptive modulation rather than pharmacological suppression [12]. ## References [5] Anisimov VN, et al. Inhibitory effect of Epitalon on colon carcinogenesis. Cancer Letters. 2002. PMID 12049808. [6] Kossoy G, et al. Epitalon and colon carcinogenesis in rats. Int J Mol Med. 2003. PMID 12964022. [7] Anisimov VN, et al. Inhibitory effect on mammary tumors in HER-2/neu mice. Int J Cancer. 2002. PMID 12209581. [8] Kossoy G, et al. Effect of epitalon on spontaneous carcinogenesis in C3H/He mice. In Vivo. 2006. PMID 16634527. [9] Khavinson VKh, Morozov VG. Peptides prolong human life. Neuroendocrinology Letters. 2003. PMID 14523363. [12] Korkushko OV, et al. Effect of epithalamin on circadian melatonin. Bull Exp Biol Med. 2004. PMID 15452611. [16] Khavinson VKh, et al. Epitalon improves eye retina condition. Neuroendocrinology Letters. 2002. PMID 12195242. [17] Yue X, et al. Epitalon protects mouse oocytes. Aging (Albany NY). 2022. PMID 35413689. [21] Overview of Epitalon — Highly Bioactive Pineal Tetrapeptide. Int J Mol Sci. 2025. PMID 40141333. [22] Al-Dulaimi et al. Epitalon increases telomere length through telomerase or ALT. Biogerontology. 2025. PMID 40908429. --- Twenty-five years of epitalon findings — counted, cited, and indexed as a research record. Not a clinic.